Today's Top Story | | |
|
- Major pharma eyes mid-priced biotech M&A deals in 2013
Big drugmakers with expired patents on major products will increasingly depend on mergers and acquisitions to increase sales, according to an analysis from Ernst & Young. Demand is expected to be high for biotech firms in the $5 billion to $20 billion range, particularly for "bolt-on" operations that can contribute to sales immediately. Xconomy/San Francisco
(1/10)
Health Care & Policy | | |
|
- Bigger, lengthier clinical trials could help in finding a cure for ALS
More than 20 experimental drugs have failed in clinical trials as treatments for amyotrophic lateral sclerosis. Biogen Idec's dexpramipexole was abandoned when it failed to help patients in a phase III trial. Steve Perrin, CEO of the ALS Therapy Development Institute, says that phase II trials should involve more patients for longer periods to determine how to proceed in phase III. "All of the drugs that have failed recently in Phase III looked promising at Phase II," he said. "The lesson here is that we need to change the design in Phase II." Xconomy/Boston
(1/10)
- Theravance and GSK submit COPD combo for EU review
GlaxoSmithKline and Theravance filed an application with the European Medicines Agency seeking approval to market Anoro, their once-daily inhaler UMEC/VI, as a maintenance treatment for symptom relief in adult patients with chronic obstructive pulmonary disease. The drug is a combination of vilanterol, a long-acting beta agonist, and umeclidinium bromide, a long-acting muscarinic antagonist. PharmaTimes (U.K.)
(1/10)
- Mesoblast's spinal treatment may enter late-stage trial this year
Mesoblast plans to launch a late-stage trial this year of NeoFuse, a mesencyhmal precursor stem cell treatment for spinal fusion, after announcing promising results from a midstage study. Patients in the Phase II trial who received 25 million mesenchymal precursor cells had higher fusion rates after 12 months than those who got bone autograft. The treatment also was associated with diminished surgical blood loss, according to the study. Australian Life Scientist
(1/11)
Company & Financial News | | |
|
- Galapagos wins $3.5M grant for antibiotics research
A Flemish agency awarded Galapagos a grant worth about $3.5 million to discover new antibiotics. The firm will work with researchers from Ghent University and Free University Brussels in this three-year project. "With this grant, we can support the search for more novel inhibitors of the antibacterial target DNA pol III alpha to fight against these difficult-to-treat bacterial species," Galapagos Chief Scientific Officer Piet Wigerinck said. Genetic Engineering & Biotechnology News
(1/10)
Food & Agriculture | | |
|
Industrial & Environmental | | |
|
- DuPont is optimistic about 2nd-generation biofuel projects
DuPont Industrial Biosciences is working on two second-generation biofuel projects it believes it can commercialize, said Jan Koninckx, global director of biofuels. The company's corn-stover facility in Nevada, Iowa, which broke ground in November, will gather stover from up to 40 miles away, provided by about 100 farmers under contract. DuPont also has high hope for its Butamax Advanced Biofuels joint venture with BP, which will be the first such to produce isobutanol from corn using a genetically modified yeast, Koninckx said. ConsumerEnergyReport.com
(1/7)
|
| |
| The Buzz(CORPORATE ANNOUNCEMENTS)
| |
|
| |
News from BIO | | |
|
-
Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
SmartQuote | | |
|
| The most valuable of all talents is that of never using two words when one will do."
--Thomas Jefferson, 3rd U.S. president
|
| |
| |
Read more at SmartBrief.com |
A powerful website for SmartBrief readers including:
|
|
|
|
|
| Recent BIO SmartBrief Issues:
- Thursday, January 10, 2013
- Wednesday, January 09, 2013
- Tuesday, January 08, 2013
- Monday, January 07, 2013
- Friday, January 04, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
|
|
© 1999-2013 SmartBrief, Inc.® Legal Information |
|